Articles tagged with Brain Tumors
Researchers found that CBD shrinks glioblastoma tumors by reducing inflammation and restoring immune balance. The compound also suppresses key proteins involved in tumor growth and spread, making it a potential novel adjunct therapy for glioblastoma patients.
Researchers have discovered that HIV drugs may be effective in treating low-grade brain tumours, specifically meningioma and acoustic neuroma. High levels of HERV-K proteins were found to stimulate the growth of these tumours, and targeted drugs have been identified to reduce their growth.
Research reveals that the parietooccipital fissure acts as an obstacle to glioma invasion, with tumor cells making a detour around it. This finding highlights the importance of this fissure in determining the invasion pattern of posterior medial temporal gliomas.
Researchers found that asthma causes immune cells to behave in a way that prevents brain tumor growth, suggesting a potential new therapeutic approach. The findings suggest reprogramming T cells to act like those in asthma patients could be a new treatment for brain tumors.
A prospective study found that MRI outperformed conventional tests and FDG PET/CT for various staging endpoints in SCLC. Whole-body MRI and FDG PET/MRI were more accurate than FDG PET/CT for assessing local invasion extent.
Investigators at Weill Cornell Medicine identified significant age-related differences in tumor characteristics across various cancers, suggesting potential for personalized treatment approaches. They found that tumors from younger patients showed advanced signs of aging and more mutations associated with aggressive disease.
In a phase III trial, elacestrant showed significant benefits in decreasing death or disease progression and increasing progression-free survival compared to standard of care. The treatment was well-tolerated with manageable side effects, offering hope for patients with ER-positive/HER2-negative metastatic breast cancer.
A UCLA research team found that PD-1 blockade initially activates T cells and conventional dendritic cells in glioblastoma, but the immune microenvironment remains dominated by immunosuppressive cells. The study suggests that combining therapies targeting other checkpoint proteins and pathways may improve treatment outcomes.
Cleveland Clinic researchers found that verubecestat, an Alzheimer's disease treatment, reduces glioblastoma progression by reprogramming tumor-associated macrophages into tumor-suppressing macrophages. This transformation leads to increased phagocytosis of tumor cells and reduced tumor growth.
Researchers at Children's National Hospital have successfully developed a personalized T cell immunotherapy that targets and kills unique proteins in individual tumor cells. This approach, combining genetic sequencing and protein identification, offers a promising treatment option for children with hard-to-treat brain tumors.
A Mount Sinai study reveals that young adult cancer patients exhibit distinct genetic hallmarks and immune system responses compared to their older counterparts. These findings suggest personalized treatment approaches for young adults with various types of cancers.
Researchers identified 166 prognostic biomarkers from long non-coding RNAs, with one biomarker, HOXA10-AS, showing high effectiveness in categorizing gliomas as low- or high-risk. The study provides potential therapeutic targets and insights into cancer biology.
A study found that patients from ethnic minority groups had lower mortality rates compared to white British people. Patients from Indian, Pakistani, and other ethnic backgrounds were 16-30% less likely to die within one year of diagnosis.
A study found that arginine treatment improved outcomes in cancer patients with brain metastases, showing a complete or partial response in nearly 78% of patients. The amino acid may be useful as an anticancer therapy when combined with radiotherapy or other treatments.
A recent study published in PLOS ONE found that combining copper ions with a drug once used for treating alcoholism kills medulloblastoma cancer cells and prevents new ones from forming. The therapy also curtails the creation of cancer stem cells, which initiate tumor growth and recurrence.
Researchers at UBC and BC Cancer developed a new test to distinguish between high-risk medulloblastoma cases requiring radiation therapy and lower-risk cases. This test has the potential to improve diagnosis and future treatment of childhood brain tumours worldwide, reducing unnecessary side effects and increasing cure rates.
Researchers at Queen Mary University of London have discovered a new way to analyze diseased and healthy cells from the same patient, revealing potential targets for individualized treatments. The study's findings could also help predict patient response to current drugs, leading to improved survival rates.
A team of researchers from Japan has developed a platform using nanofibers to capture and control the migration of brain tumor cells, including glioblastoma multiforme. The study found that varying fiber densities can slow or speed up cell movement, leading to the creation of 'cell traps' that can restrict tumor cell growth.
A new study found that translocator protein 18 kDa (TSPO) correlates with worse survival outcomes in male glioblastoma patients compared to females. The variation in the protein's structure is associated with shorter overall and progression-free survival times, suggesting its potential as a prognostic biomarker.
Researchers at Sunnybrook Health Sciences Centre have successfully delivered antibody therapy to breast cancer metastases in the brain using focused ultrasound. The treatment, which temporarily opens the blood-brain barrier, has shown promising results with tumor size reductions of up to 21% in patients.
A new antibody delivery technology enhances anti-PD-L1 antibody accumulation in glioblastoma by 33-fold, achieving a 60% complete response rate with long-term immune memory. The technology also suppresses immune-related adverse events.
Researchers developed a gel made of fibrin that improved the effectiveness of CAR-T cell immunotherapy for glioblastoma by enhancing T cell distribution and preventing tumor recurrence. In mouse studies, the gel showed promising results, with 64% of treated mice being tumor-free after 94 days.
Researchers found that metformin suppressed glucose metabolism and killed cancer cells in group A posterior fossa ependymomas, a type of childhood brain tumor. The study's senior author believes this opens a promising possibility for therapeutic suppression of the epigenetic changes driving these tumors.
Researchers at Weill Cornell Medicine have profiled individual cells from patients' brain tumors in unprecedented detail, revealing distinct states and programming marks that could be targeted with future drugs. The study offers insights into glioma dynamics and may lead to better detection, staging, monitoring, and treatment methods.
A new treatment approach targets angiogenesis, inflammation, and oxidative stress in glioblastoma multiforme, reducing tumor volume and growth by up to 89%. The combination of LAU-0901, Elovanoids, and Avastin shows promise in improving survival rates for patients with this deadly cancer.
Researchers found low T cell infiltration in glioblastoma tissue, with higher CD8+ TIL density at recurrence. The study suggests that immune checkpoint inhibition may not be effective due to limited tumour-infiltrating lymphocyte density.
Researchers discovered that new mutations in the BRAF gene can lead to gliomas growing back after treatment, suggesting personalized approaches to therapy. The study also explored potential impacts of COVID-19 vaccines on menstruation.
Researchers analyzed data from over 3,200 brain metastatic tumors and discovered that different types of cancer tend to spread to specific parts of the brain. The study's findings may help predict where a particular cancer will metastasize and inform treatment strategies.
Scientists at Ann & Robert H. Lurie Children's Hospital of Chicago discovered a surprising link between growth factor receptor PDGFRA and hypomyelination in mouse models. The study suggests that blocking this receptor could be a novel strategy to treat myelination disorders like multiple sclerosis.
A nationwide study of 295,000 brain cancer patients reveals significant differences in survival and incidence based on sex and age. The findings suggest that males have higher incidence rates, while females have longer survival rates at almost every age group, except among children aged 0-9 years.
Researchers at Uppsala University developed a new method to track individual cancer cells and their offspring over time. The study found that brain tumour cells are hierarchically organised, but with some degree of flexibility, and that drug treatment influences cell organisation. This breakthrough may lead to the development of target...
A team of researchers led by CU Cancer Center member Jean Mulcahy Levy examined tumor samples before and after treatment with a targeted medicine. They found additional mutations that can create resistance to the therapy, highlighting the need for new treatments or combination therapies.
Researchers develop a novel cell reprogramming strategy to transform glioma cells into non-proliferative neurons. This approach shows promise in slowing down the growth of GBMs and overcoming harmful side effects of conventional treatments.
Researchers found that ribociclib achieved pharmacologically-relevant concentrations in tumor tissue, while everolimus showed minimal penetration. The combination is promising for brain cancer treatment and could lead to new therapeutic drug combinations.
A new study has identified the periaqueductal gray as a critical hub for changes in spiritual identification, surprising researchers who previously thought it was associated with higher brain regions. The discovery could have significant implications for understanding spirituality's role in managing physical and emotional pain.
Researchers at McGill University identified proteins that drive cancer stem cells in brain tumours. Targeting the protein galectin1 may provide a more effective treatment for glioblastoma when combined with radiation therapy. The study found significant improvement in tumour response to radiation therapy, resulting in expanded lifespan.
A new study suggests that a treatment for canine glioblastoma may also be effective in humans, with some dogs experiencing significant tumor shrinkage. The treatment uses an immunotherapy drug called STING agonist, which induced a robust immune response against cancer cells.
A study by the Center for Cell-Based Therapy in São Paulo, Brazil, has discovered a set of biomarkers that can be used to predict which patients with glioblastoma may have tumors resistant to radiation therapy. The genetic signature helps doctors choose the best treatment option for these patients.
Researchers at Tel Aviv University successfully printed the first entirely active and viable glioblastoma tumor using a 3D printer. The 3D-bioprinted model includes functional blood vessels that simulate a real tumor, making it a promising tool for predicting treatment efficacy and drug development.
Researchers at Houston Methodist used a helmet generating a noninvasive oscillating magnetic field to treat end-stage recurrent glioblastoma. The treatment resulted in a 31% reduction of the tumor mass, with significant shrinkage appearing to correlate with the treatment dose.
Researchers found that losartan treatment reduced inflammatory signaling and swelling in vestibular schwannomas, preventing hearing loss. The drug also increased oxygen delivery to enhance the effectiveness of radiation therapy, potentially lowering radiation doses needed to control tumor growth.
Researchers studied the mechanism of liposome accumulation in tumors using fluorescent microscopy and imaging. They found that different lipids have varying abilities to accumulate in tumors, with one lipid type showing remarkable extravasation and reaching immune and tumor cells.
Researchers at Uppsala University discovered lymph node-like structures in brain cancer patients where immune cells can be activated. Immunotherapy enhanced these structure formation in a mouse model, suggesting new ways to regulate the anti-tumour response.
A new study reveals similarities between glioblastoma and melanoma, as well as unique immunosuppressive factors specific to glioblastoma microenvironment. This framework can be used to uncover pathophysiological and molecular features that determine the effectiveness of immunotherapies.
ASU engineering researchers have discovered a new neural stem cell state that could be key to unlocking new methods of brain cancer treatment. The team found that the quiescent Neural G0 state is independent of a tumor's proliferation rate and can potentially be targeted for new drug treatments.
A study coordinated by the University of Trento identified the cell of origin of medulloblastoma, a common and aggressive childhood brain cancer. The researchers used organoids, three-dimensional models of tumor tissue, to understand the genetic mechanisms responsible for this type of brain cancer.
A recent study published in Scientific Reports found that carefully considered surgical treatment improves the prognosis for elderly brain tumour patients. Almost half of patients who had ended up in institutional care due to a brain tumour were able to return home thanks to surgery.
Researchers at Nagoya University have developed a simple urine test that can detect brain tumors with high accuracy, using microRNAs as biomarkers. The new device can extract more microRNAs from just a milliliter of urine than conventional methods, and shows promise for early diagnosis and treatment.
A new radiopharmaceutical, 18F-DASA-23, has successfully visualized the 'master switch' protein PKM2 in glioblastoma patients. This allows for non-invasive assessment of treatment response and potential early detection of therapeutic effectiveness.
A British man diagnosed with IDH1-mutant glioblastoma has lived with a growing tumor for over 80 months on a ketogenic diet. Researchers believe this reflects the benefits of using the body's own metabolism to fight cancer, offering a non-toxic alternative to chemotherapy and radiation therapy.
Researchers discover that children with average risk medulloblastoma can receive a smaller volume of radiation boost without reducing survival rates. However, reducing the dose of radiation given to the whole brain and spine over six weeks had a negative impact on survival.
Researchers discovered that neural activity underlying visual signals can ignite and feed tumors in young children with neurofibromatosis type 1. The study found that raising mice in the dark or treating them with an experimental cancer drug slowed tumor growth, suggesting a key role for controlling neuronal activity.
Researchers found that light exposure triggers the formation of brain tumors in genetically prone mice, which could help prevent similar tumors in children at high risk. The study suggests using cool sunglasses or repurposing drugs to block unwanted neuronal activity and reduce tumor growth.
Scientists discover a way to reactivate paralyzed immune cells against IDH-mutant gliomas, leading to improved vaccine effectiveness. The researchers identified the molecular mechanism behind the 'immune paralysis' caused by cancer-promoting metabolic products and found a substance that deactivates a key immune system regulatory molecule.
A research team from the University of Münster has identified a new mechanism regulating cell growth in tuberous sclerosis complex (TSC), which affects one in 10,000 newborns. The study reveals how mutations can disrupt protein binding through a 'burr effect', leading to uncontrolled cell growth and tumour formation.
Researchers at Massachusetts General Hospital have developed a strategy to reprogram regulatory T cells in the brain to attack glioblastoma tumors. By targeting a specific receptor on these cells, they can convert them into tumor-fighting immune cells, offering a possible solution to overcome resistance to immunotherapy.
A team of researchers has developed a delivery system for RNA-based therapy in brain tumors using ultrasound and nanoparticles. The technique allows for increased tumor cell death and reduced harmful protein production, with potential for minimal side effects.
The review highlights focused, high-dose radiation's potential to destroy small tumors with minimal impact on surrounding normal tissue. Researchers aim to tailor radiotherapy to optimize benefits and minimize risks through advanced techniques like stereotactic body radiation therapy and radiosurgery.
A team of researchers from Virginia Tech and City of Hope aim to improve CAR-T cell therapy for glioblastoma multiforme by studying the impact of fluid flow on the treatment's success. They believe they can use fluid flow to encourage T cells to move deeper into tumors and kill invading cancer cells.
A new method called XYZeq allows researchers to map variation across cells in a tissue or tumor, gaining insight into their spatial location and function. The technique enables the analysis of cellular patterns in complex environments like cancerous tumors and other organs.